Clinical Trial Update: A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating systemic exposure, pharmacodynamics, safety and tolerability of the inhaled triple therapy fluticasone furoate/umeclidinium/vilanterol …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Furoate (fluticasone furoate)
• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
• Umeclidinium (umeclidinium)
• Vilanterol (vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED